These findings provided mechanistic rationale to test PI3Kα inhibitor in ESCC patients with amplified CCND1 and its combination with CDK4/6 inhibitors for the therapy of ESCC with proficient Rb. The gene discussed is CCND1; the disease is esophageal squamous cell carcinoma.